Platelets and Fibrinolysis

References

• Marder V J, Sherry S. Thrombolytic therapy: current status. N Engl Med 1988; 318: 1512–1520
   PubMed Web of Science ®Google Scholar
• Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med 1988; 319: 925–931
   PubMed Web of Science ®Google Scholar
• Yasuda T, Gold H K, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714–722
   PubMed Web of Science ®Google Scholar
• Jang I-K, Gold H K, Ziskind A A, et al. Differential sensitivity of erythrocyte-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920–928
   PubMed Web of Science ®Google Scholar
• Miles L A, Plow E F. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303–4311
   PubMedGoogle Scholar
• Miles L A, Ginsberg M H, White J G, Plow E F. Plasminogen interacts with human platelets through two distinct mechanisms. J Biol Chem 1986; 77: 2001–2009
   Google Scholar
• Gao S-W, Morser J, McLean K, Shuman M A. Differential effect of platelets on plasminogen activation by tissue plasminogen activator, urokinase, and streptokinase. Thromb Res 1990; 58: 421–433
   PubMed Web of Science ®Google Scholar
• Plow E F, Collen D. The presence and release of α2-antiplasmin from human platelets. Blood 1981; 58: 1069–1074
   PubMed Web of Science ®Google Scholar
• Erickson L A, Ginsberg M H, Loskutoff D J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465–1472
   PubMed Web of Science ®Google Scholar
• Kruithof E K, Tran-Thang C, Bachmann F. Studies on the release of plasminogen activator inhibitor from human platelets. Thromb Haemost 1986; 55: 201–205
   PubMed Web of Science ®Google Scholar
• Rudd M A, Amarante P, Smick D, George D, Loscalzo J. Temporal effects of tissue plasminogen activator infusion in rabbits on platelet aggregation ex vivo. Circ Res 1990; 67: 1175–1181
   PubMed Web of Science ®Google Scholar
• Walsh P N. Platelet-mediated coagulant protein interactions in hemostasis. Semin Hematol 1985; 22: 178–186
   PubMedGoogle Scholar
• Jennings L, Philips D. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent IIb-III complex. J Biol Chem 1982; 257: 10458–10463
   PubMed Web of Science ®Google Scholar
• Peerschke E I B. The platelet fibrinogen receptor. Semin Hematol 1985; 22: 241–259
   PubMed Web of Science ®Google Scholar
• Gralnick H R, Williams S B, Coller B S. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated by thrombin. Blood 1984; 64: 797–800
   PubMed Web of Science ®Google Scholar
• Plow E F, Ginsberg M H. Cellular adhesion GPIIb/IIIa as a prototype adhesion receptor. Prog Hemost Thromb 1989; 9: 117–156
   PubMedGoogle Scholar
• Weiss H J, Hawiger J, Ruggeri Z, Turitto V T, Thiagarajan P, Hoffman T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb/IIIa complex at high shear rate. J Clin Invest 1989; 83: 288–297
   PubMed Web of Science ®Google Scholar
• Cheresh D A, Berliner S A, Vincente V, Ruggeri Z M. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58: 945–953
   PubMed Web of Science ®Google Scholar
• Newman P J, McEver R P, Doers M P, Kunicki T J. Synergistic action of two murine monoclonal antibodies that inhibit ADP-induced platelet aggregation without blocking fibrinogen binding. Blood 1987; 69: 668–676
   PubMed Web of Science ®Google Scholar
• Isenberg W M, Bainton D F, Newman P J. Monoclonal antibodies bound to subunits of the integrin GPIIb/IIIa are internalized and interfere with filopodia formation and platelet aggregation. Blood 1990; 76: 1564–1571
   PubMed Web of Science ®Google Scholar
• Pytela R, Piersbacher M D, Ginsberg M H, Plow E F, Ruoshlati E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559–1562
   PubMed Web of Science ®Google Scholar
• Kloczewiak M, Timmons S, Lukas T J, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the δ chain. Biochemistry 1984; 23: 1767–1774
   PubMed Web of Science ®Google Scholar
• Plow E F, Srouji A H, Meyer D, Marguerie G A, Ginsberg M H. Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem 1984; 259: 5388–5391
   PubMed Web of Science ®Google Scholar
• Parise L V, Helgerson S L, Steiner B, Nanizzi L, Phillips D R. Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb/IIIa. J Biol Chem 1987; 262: 12597–12602
   PubMed Web of Science ®Google Scholar
• Altieri D C, Agbanyo F R, Plescia J, Ginsberg M H, Edgington T S, Plow E F A. unique recognition site mediates the interaction of fibrinogen with the leucocyte integrin Mac-1 (CD11b/CD18). J Biol Chem 1990; 265: 12119–12122
   PubMedGoogle Scholar
• Kirchhofer D., Gailit J, Ruoshlati E, Grzesiak J, Piersbacher M D. Cation-dependent changes in the binding specificity of the platelet receptor GPIIb/IIIa. J Biol Chem 1990; 265: 18525–18530
   PubMed Web of Science ®Google Scholar
• Shattil S J, Brass L F, Bennett J S, Pandhi P. Biochemical and functional consequences of dissociation of the platelet membrane GPIIb/IIIa complex. Blood 1985; 66: 92–98
   PubMed Web of Science ®Google Scholar
• Pidard D, Didry D, Kunicki T J, Nurden A T. Temperature-dependent effects of EDTA on the membrane glycoprotein IIb/IIIa complex and platelet aggregability. Blood; 1986; 67: 604–611
   PubMed Web of Science ®Google Scholar
• Fujimura K, Phillips D R. Calcium cation regulation of glycoprotein IIb/IIIa complex formation in platelet plasma membrane. J Biol Chem 1983; 258: 10247–10252
   PubMed Web of Science ®Google Scholar
• Winters K J, Eisenberg P R, Jaffe A S, Santoro S A. Dependence of plasmin-mediated degradation of platelet adhesive receptors on temperature and Ca+ +. Blood 1990; 76: 1546–1557
   Google Scholar
• Peerschke E I B. Irreversible platelet fibrinogen interactions occur independently of fibrinogen α chain degradation and are not mediated by intact platelet membrane glycoprotein IIb/IIIa complexes. J Lab Clin Med 1988; 111: 84–92
   Google Scholar
• Peerschke E I B. Decreased accessibility of platelet-bound fibrinogen to antibody and enzyme probes. Blood 1989; 74: 682–689
   PubMedGoogle Scholar
• Fitzgerald D J, Catella F, Roy L, FitzGerald G A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142–150
   PubMed Web of Science ®Google Scholar
• Kerins D M, Roy L, FitzGerald G A, Fitzgerald D J. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 1989; 80: 1718–1725
   PubMed Web of Science ®Google Scholar
• Fitzgerald D J, Wright F, FitzGerald G A. Increased thromboxane biosynthesis during coronary thrombolysis: evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator. Circ Res 1989; 65: 83–86
   PubMed Web of Science ®Google Scholar
• Leonard E F, Turitto V T, Vroman L. Blood in contact with natural and artificial surfaces. Ann N Y Acad Sci 1987; 516: 380–397
   Google Scholar
• Ikeda Y, Mitsuro M, Araki Y, Watanabe K, Ando Y, Itagaki I, Mori Y, Ichitani M, Sakai K. Importance of fibrinogen and platelet membrane glycoprotein IIb/IIIa in shear induced platelet aggregation. Thromb Res 1988; 51: 157–163
   Google Scholar
• Niewiarowski S, Senyi A F, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. J Clin Invest 1973; 52: 1647–1659
   PubMedGoogle Scholar
• Guccione M A, Kinlough-Rathbone R L, Packam M A, Harfenist E J, Rand M L, Greenberg J P, Perry D W, Mustard J F. Effect of plasmin on rabbit platelets. Thromb Haemost 1985; 53: 8–14
   PubMedGoogle Scholar
• Schafer A I, Maas A K, Ware A, Johnson P C, Rittenhouse S E, Salzman E W. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 1986; 78: 73–78
   PubMedGoogle Scholar
• Puri R N, Zhou F, Colman R W. Plasmin-induced platelet aggregation is accompanied by cleavage of aggregin and indirectly mediated by calpain. Am J Physiol 1990; 259: C862–C8687
   Google Scholar
• Lu J, et al. Role of active center and lysine binding sites of plasma in plasmin-induced platelet activation and disaggregation. Thromb Haemostas 1991; 65: 67–72
   Google Scholar
• Miller J L, Katz A J, Feinstein M B. Plasmin inhibition of thrombin-induced platelet aggregation. Thromb Diath Haemorrh 1975; 33: 286–309
   PubMedGoogle Scholar
• Loscalzo J, Vaughan D E. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749–1755
   Google Scholar
• Vaughan D E, Loscalzo J. Comparative effects of plasminogen activators on platelet disaggregation. J Vasc Med Biol 1989; 1: 27–31
   Google Scholar
• Torr S R, Winters K J, Santoro S A, Sobel B E. The nature of interactions between tissue-type plasminogen activator and platelets. Thromb Res 1990; 59: 279–293
   PubMed Web of Science ®Google Scholar
• Adelman B, Michelson A D, Loscalzo J, Greenburg J, Handin R I. Plasmin effect on glycoprotein in Ib-von Willebrand factor interactions. Blood 1985; 65: 32–40
   PubMed Web of Science ®Google Scholar
• Adelman B, Michelson A D, Greenberg J, Handin R I. Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood 1986; 68: 1280–1284
   PubMedGoogle Scholar
• Michelson A D, Barnard M R. Plasmin-induced redistribution of platelet glycoprotein Ib. Blood 1990; 76: 2005–2010
   PubMed Web of Science ®Google Scholar
• Cramer E M, He L, Soria C, Tenza D, Caen J P. Differential redistribution of platelet glycoprotein Ib and IIb/IIIa by plasmin stimulation. Blood 1990; 76: 1803, abstract
   Google Scholar
• Fry E T A, Grace A M, Sobel B E. Interactions between pharmacologic concentrations of plasminogen activators and platelets. Fibrinolysis 1989; 3: 127–136
   Google Scholar
• Adnot S, Ferry N, Hanoune J, Lacombe M-L. Plasmin a possible physiological modulator of the human platelet adenylate cyclase system. Clinical Science 1987; 72: 467–473
   Google Scholar
• Kreager J A, Devine D V, Greenberg C S. Cytofluorometric identification of plasmin-sensitive factor XIIIa binding to platelets. Thromb Haemost 1988; 60: 88–93
   PubMedGoogle Scholar
• Jerushalmy Z, Zucker M B. Some effects of fibrinogen degradation products (FDP) on blood platelets. Thromb Diath Haemorrh 1966; 15: 413–419
   PubMedGoogle Scholar
• Stachurska J, Lopaciuk S, Gerdin B, Saldeen T, Koroscik A, Kopec M. Effect of proteolytic degradation products of human fibrinogen and of human factor VIII on platelet aggregation and vascular permeability. Thromb Res 1979; 15: 663–672
   PubMedGoogle Scholar
• Donati M B, de Gaetano G, Vermylen J, Verstraete M. Inhibition of human platelet aggregation by plasmin digest of human factor VIII. Blood, 42: 749–751
   Google Scholar
• Culasso D E, Donati M B, de Gaetano G, Vermylen J, Verstraete M. Inhibition of human platelet aggregation by plasmin digests of human and bovine fibrinogen preparations: role of contaminating factor VIII-related material. Blood, 44: 169–175
   Google Scholar
• Hamilton K K, Fretto L J, Grierson D S, McKee P A. Effects of plasmin on von Willebrand factors multimers. Degradation in vitro and stimulation and release in vivo. J Clin Ivest 1985; 76(1)261–270
   Google Scholar
• Andersen J C, Switzer M E, McKee P. Support of ristocetin-induced platelet aggregation by procoagulant-inactive and plasmin-cleaved forms of human factor VIII/von Willebrand factor. Blood 1980; 55: 101–108
   Google Scholar
• Pasqua J J, Pisso S V. The role of ligand-ligand interactions in competition by fibrinogen and fibrin degradation products for fibrinogen binding to human platelets. Biochem Biophys Acta 1983; 757: 282–287
   Google Scholar
• Niewiarowski S, Budzinski A Z, Lipinski B. Significance of the intact polypeptide chains of human fibrinogen in ADP-induced platelet aggregation. Blood 1977; 49: 635–644
   PubMed Web of Science ®Google Scholar
• Vaughan D E, Mendelsohn M E, Declerck P J, Van Houtte E, Collen D, Loscalzo J. Characterization of the binding of human tissue-type plasminogen activator to platelets. J Biol Chem 1989; 264: 15869–15874
   Google Scholar
• Weitz J I, Cruisckshank M K, Thong B, et al. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 1988; 82: 1700–1707
   PubMedGoogle Scholar
• Eisenberg P R, Sherman L A, Jaffe A S. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527–531
   PubMedGoogle Scholar
• Owen J, Friedman K D, Grossman B A, Wilkins C, Berke A D, Powers E R. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616–620
   PubMed Web of Science ®Google Scholar
• Lee C D, Mann K G. Activation/inactivation of human factor V by plasmin. Blood 1989; 73: 185–190
   Google Scholar
• Francis C W, Markham R E, Barlow G H, Florack T M, Dobrzynski D M, Marder V J. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220–225
   Google Scholar
• Miletich J P, Jackson C M, Majerus P W. Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci USA 1977; 74: 4033–4036
   PubMed Web of Science ®Google Scholar
• Leung L L K, Harpel P C, Nachman R L, Rabellino E M. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62: 1016–1021
   PubMedGoogle Scholar
• Vaughan D E, Kirschenbaum J, Loscalzo J. Steptokinase-induced, antibody-mediated platelet aggregation—A potential cause of clot propagation in vivo. J Am Coll Cardiol 1988; 11: 1343–1348
   PubMed Web of Science ®Google Scholar
• Vaughan D E, Van Houtte E, Declerck P J, Van der Werf F, Collen D. Prevalence and mechanism of steptokinase-induced platelet aggregation. Circulation 1991, in press
   Google Scholar
• Heptinstall S, Berridge D C, Judge H. Effects of steptokinase and recombinant tissue plasminogen activator on platelet aggregation in whole blood. Platelets 1990; 1: 177–187
   PubMedGoogle Scholar
• Weitz J I, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385–391
   PubMed Web of Science ®Google Scholar
• Gilboa N, Villanueva G B, Fenton J W. Inhibition of fibrinolytic enzymes by thrombin inhibitors. Enzyme 1988; 40: 144–148
   PubMedGoogle Scholar
• Cella G, Scattolo N, Luzzatto G, Girolami A. Effects of low-molecular-weight heparin on platelets as compared with commercial heparin. Res Exp Med (Berl) 1984; 184: 227–229
   PubMedGoogle Scholar
• Mastacchi R, Barbanti M, Bianchini P, Osima B. Interaction of a new low molecular weight heparin (OP/ LMWH) with human platelets. Agents Actions 1986; 17: 512–514
   Google Scholar
• Gold H K, Coller B S, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670–677
   PubMed Web of Science ®Google Scholar
• Golino P, Ashton J H, Glas-Greenwalt P, McNatt J, Buja L L, Willerson J T. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988; 77: 678–682
   PubMedGoogle Scholar
• Cameron H A, Philips R, Ibbotson R M, Carson P H M. Platelet size in myocardial infarction. Br Med J 1983; 287: 449–451
   PubMed Web of Science ®Google Scholar
• Martin J F, Trowbridge E A, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane A2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443–460
   PubMed Web of Science ®Google Scholar
• Milner P C, Martin J F. Shortened bleeding time in acute myocardial infarction and its relation to platelet mass. Br Med J 1985; 290: 1767–1770
   PubMedGoogle Scholar
• Trowbridge E A, Slater D N, Kishk Y T, Woodcock B W, Martin J F. Platelet production in myocardial infarction and sudden cardiac death. Throm Haemost 1984; 52: 167–171
   Google Scholar
• Trowbridge E A, Martin J F. The platelet volume distribution: a signature of the prethrombotic state in coronary heart disease?. Thromb Haemost 1987; 58: 714–717
   PubMed Web of Science ®Google Scholar
• Gurewich V, Pannell R. A comparative study of the efficacy and specificity of tissue plasminogen activator and prourokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res 1986; 44: 217–221
   Google Scholar
• Kunitada S, FitzGerald G A, Fitzgerald D J. Decreased binding of tissue-type plasminogen activator to human thrombi rich in platelets. Clin Res 1990; 38: 470A, abstract
   Google Scholar
• Francis C W, Marder V J. Rapid formation of large molecular weight α-polymers in cross-linked fibrin induced by high factor XIII concentrations: role of platelet factor XIII. J Clin Invest 1987; 80: 1459–1463
   PubMedGoogle Scholar
• Shebuski R J., Sitko G R, Claremon D A, Baldwin J J, Remy D C, Stern A M. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990; 75: 1455–1459
   PubMedGoogle Scholar
• Grines C L, Topol E J, Bates E R, Juni J E, Walton J A, O'Neil W W. Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome. Am Heart J 1988; 115: 1–6
   PubMedGoogle Scholar
• Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction: value of combined thrombolytic and vasodilator therapy. N Engl J Med 1987; 317: 1055–1061
   PubMed Web of Science ®Google Scholar
• Vaughan D E, Plavin S R, Schafer A I, Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989; 73: 1213–1217
   Google Scholar
• Marcus A J. Transcellular metabolism of eicosanoids. Prog Hemostas Thromb 1986; 8: 127–142
   PubMedGoogle Scholar
• Oates J A, Fitzgerald G A, Branch R A, Jackson E K, Knapp H R, Roberts L J. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988; 319: 689–698
   PubMed Web of Science ®Google Scholar
• Shebuski R J, Smith J M, Storer B L, Granett J R, Bugelski P J. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog. J Pharm Exp Ther 1988; 246: 790–797
   Google Scholar
• Gresele P J, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis: studies with combined thromboxane synthase inhibition and thromboxane receptor antagonists. J Clin Invest 1987; 80: 1435–1445
   PubMed Web of Science ®Google Scholar
• Fitzgerald D J, Fragetta J, FitzGerald G A. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest 1988; 82: 1708–1713
   PubMed Web of Science ®Google Scholar
• Topol E J, Ellis S G, Califf R M. and the TAMI-4 Study Group Combined tissue-type plasminogen activator and prostacyclin and therapy for acute myocardial infarction. J Am Coll Cardiol 1989; 14: 877–881
   PubMed Web of Science ®Google Scholar
• Nicolini F A, Mehta J L, Nichols W W, Saldeen T G, Grant M. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation 1990; 81: 1115–1122
   PubMed Web of Science ®Google Scholar
• Kerins D M, FitzGerald G A, Fitzgerald D J. Interaction of a prostacyclin analog and tissue plasminogen activator (t-PA) during coronary thrombolysis. Clin Res 1988; 37: 217A, abstract
   Google Scholar
• Schumacher W A, Lee E C, Luchessi B R. Augmentation of streptokinase-induced thrombolysis by heparin and prostacyclin. J Cardiovasc Pharmacol 1985; 7: 739–746
   Google Scholar
• Coller B S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GPIIb/IIIa complex. J Clin Invest 1985; 76: 101–107
   PubMed Web of Science ®Google Scholar
• Fitzgerald D J, Hanson M, Fitzgerald G A. Attenuation of the thrombolytic response to urokinase by platelets is minimal. Circulation 1989; 80: 11–422, abstract
   Google Scholar
• Mickelson J K, Simpson P J, Cronin M, et al. Antiplatelet antibody 7E3 prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 1990; 81: 617–627
   Google Scholar
• Haverstick D M, Cowan J F, Yamada K M, Santoro S A. Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synethetic tetrapeptide derived from the cell-binding domain of fibronectin. Blood 1985; 83: 288–297
   Google Scholar
• Gartner T K, Bennett J S. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 1985
   Google Scholar
• Dennis M S, Henzel W J, Pitti R M, et al. Platelet glycoprotein IIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 1989; 87: 2471–2475
   Web of Science ®Google Scholar
• Huang T-F, Holt J C, Lukasiewicz H, Niewiarowski S. Trigramin: a low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb/IIIa complex. J Biol Chem 1987; 262: 16157–16163
   PubMed Web of Science ®Google Scholar
• Gan Z-R, Gould R J, Jacobs J W, Friedman P A, Polokoff M A. Echistatin a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem 1988; 263: 19827–19832
   PubMed Web of Science ®Google Scholar
• de Clerck F, Xhonneux B, Leysen J, Ganssen P A. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharm 1984; 33: 2807–2811
   PubMed Web of Science ®Google Scholar
• Ashton J H, Benedict C R, Fitzgerald C, Raheja S, Taylor A, Campbell W B, Buja L M, Willerson J Y. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73: 572–578
   PubMed Web of Science ®Google Scholar
• Ashton J H, Ogletree M L, Michel I M, et al. Cooperative mediation of serotonin S2 and thromboxane A2. Circulation 1987; 76: 952–958
   PubMed Web of Science ®Google Scholar
• Radomski M W, Palmer R M, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482–1489
   PubMed Web of Science ®Google Scholar
• Stamler J S, Mendelsohn M E, Amarante P, et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989; 65: 789–795
   PubMed Web of Science ®Google Scholar
• Folts J D, Stamler J, Loscalzo J. Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation 1991; 83: 2122–2127
   Google Scholar
• Gruber A, Griffin J H, Harker L A, Hanson S R. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639–642
   PubMed Web of Science ®Google Scholar
• Heras M, Chesebro J H, Penny W J, Bailey K R, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657–665
   PubMed Web of Science ®Google Scholar
• Hanson S R, Harker L A. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone. Proc Natl Acad Sci (USA) 1988; 85: 3184–3188
   PubMed Web of Science ®Google Scholar
• Kikumoto R, Tamaoe Y, Tezuka T, et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolyl)sulfonyl]-L-arginyl]-2-piperidine-carboxylic acid. Biochemstry 1984; 23: 85–90
   PubMed Web of Science ®Google Scholar
• Fitzgerald D J, FitzGerald G A. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 1989; 86: 7585–7590
   Google Scholar
• Johnstone M J, Andrews T, Ware J. A Bleeding time prolongation with streptokinase and its reversal with DDAVP. Circulation 1990; 82: 2142–2151
   Google Scholar